Table 3 |
||||||||||
|
Total and differential cell counts at baseline and the standard mean difference (SMD) in cell counts between intervention group and placebo group after treatment. |
||||||||||
|
Source |
Total cells |
Neutrophils |
Lymphocytes |
Eosinophils |
Macrophages |
|||||
|
Number (× 104/mL) |
SMD (95% CI) |
Number (× 104/mL) |
SMD (95% CI) |
Number (× 104/mL) |
SMD (95% CI) |
Number (× 104/mL) |
SMD (95% CI) |
Number (× 104/mL) |
SMD (95% CI) |
|
|
|
||||||||||
|
Yildiz [22] |
350.0 |
-0.6 (-1.6 to 0.4) |
260.0 |
-2.2 (-3.4 to -1.0) |
3.5 |
-0.5 (-1.4 to 0.5) |
7.0 |
-1.1 (-2.1 to -0.1) |
80.0 |
0.2 (-0.5 to 0.9) |
|
Confalonieri [20] |
219.0 |
-0.4 (-1.1 to 0.3) |
158.8 |
-3.4 (-4.5 to -2.3) |
6.6 |
-0.5 (-1.2 to 0.2) |
6.2 |
-0.6 (-1.3 to 0.1) |
45.0 |
-0.3 (-0.9 to 0.3) |
|
Mirici [21] |
196.5 |
-1.0 (-1.7 to -0.3) |
146.5 |
-7.5 (-9.3 to -5.6) |
1.6 |
-0.7 (-1.4 to -0.1) |
1.6 |
0.2 (-0.4 to 0.8) |
38.2 |
0.5 (-0.5 to 1.5) |
|
Sugiura [7] |
165.7 |
0.2 (-0.8 to 1.2) |
102.9 |
0.1 (-0.9 to 1.1) |
6.1 |
0.04 (-0.9 to 1.0) |
4.5 |
-0.2 (-1.2 to 0.8) |
52.0 |
-0.3 (-1.1 to 0.5) |
|
Culpitt [19] |
165.0 |
-0.3 (-1.1 to 0.5) |
145.0 |
-0.4 (-1.2 to 0.4) |
NR |
NR |
NR |
NR |
25.0 |
-0.2 (-0.9 to 0.6) |
|
Keatings [18] |
6.3* |
-0.1 (-0.9 to 0.7) |
4.3* |
-0.4 (-1.1 to 0.4) |
6.0* |
0.0 (-0.7 to 0.8) |
0.2* |
-0.2 (-1.0 to 0.6) |
1.8* |
0.2 (-0.7 to 1.2) |
|
Pooled Summary |
-0.4 (-0.8 to -0.1) |
-2.2 (-3.8 to -0.5) |
-0.4 (-0.7 to -0.1) |
-0.3 (-0.6 to 0.1) |
-0.02 (-0.3 to 0.3) |
|||||
|
|
||||||||||
|
* cell count/ml Abbreviations: NR, not reported/not calculable. |
||||||||||
|
Gan et al. BMC Pulmonary Medicine 2005 5:3 doi:10.1186/1471-2466-5-3 |
||||||||||
